Table 2.

Outcome measures with matching cohorts

OutcomeMidazolam-Matched Cohort (n=698)Propofol-Matched Cohort (n=698)P
ValueOR
(95%CI)Adjusted OR (95%CI)a
AKI (any stage)470 (67.3)384 (55.0)<0.0010.59 (0.48 to 0.74)0.58 (0.48 to 0.72)
AKI stage 1135 (19.3)139 (19.9)1.04 (0.80 to 1.35)1.04 (0.80 to 1.36)
AKI stage 2172 (24.6)130 (18.6)<0.0010.70 (0.54 to 0.91)0.68 (0.53 to 0.88)
AKI stage 3163 (23.4)115 (16.5)0.65 (0.50 to 0.85)0.65 (0.50 to 0.85)
Oliguria (<400 ml/d)b123/627 (19.6)73/591 (12.4)0.0010.57 (0.42 to 0.78)0.58 (0.42 to 0.79)
Diuretic use100 (14.3)60 (8.5)0.0010.56 (0.40 to 0.79)0.55 (0.39 to 0.78)
Cumulative fluid balance >5% body wt407 (58.3)350 (50.1)0.010.73 (0.59 to 0.91)0.72(0.58 to 0.90)
RRT41 (5.9)24 (3.4)0.030.57 (0.34 to 0.96)0.57 (0.34 to 0.96)
ICU mortality207 (29.7)102 (14.6)<0.0010.40 (0.31 to 0.87)0.40 (0.31 to 0.82)
  • Except for ICU mortality, all outcomes were considered in the first 7 days of intensive care unit stay. ICU, intensive care unit; OR, odds ratio; 95% CI, 95% confidence interval.

  • a Adjusted for aminoglycoside and sepsis.

  • b Urine output was accessible in 1218 patients (87.3%).